The combination of anti-angiogenic drugs with PD-1/PD-L1 blockades has demonstrated the ability to overcome the immunosuppressive impact and carry out an optimal synergistic anti-tumor effect [22,24]. This evidence concerns the gene CD274 and neoplasm.